Expression of MicroRNA-221 in Korean Patients with Multiple Myeloma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Multiple myeloma (MM) is the leading cause of death among hematologic neoplasms. Recently, microRNA has been reported to be useful in the diagnosis of multiple myeloma. This study examined whether miR-221 could be used as a diagnostic marker for multiple myeloma. The study was performed on 20 patients with multiple myeloma without any other hematological diseases. MicroRNA extraction was performed using formalin-fixed paraffin-embedded (FFPE) tissues obtained from the bone marrow of patients with multiple myeloma. miR-15a, miR-16, miR-21, miR-181a, and miR-221 were selected as the microRNA target genes for multiple myeloma. The significance of microRNA was based on a fold change of ＜1.5. To quantify the fold changes, data normalized to the human gene, SNORD43, were used as the values of the patient group. Fold change values greater than 1.5 were defined as “overexpression”, whereas values less than -1.5 were defined as “underexpression”. Of note, 65.0% (13/20) of samples showed significant “overexpression” in the levels of miR-221 expression and plasma cells with a group of more and less than 30% in MM patients did not show any significance of plasma cell (P＜0.05). The results of other studies showing a correlation between the expression of miR-221 and MM in Caucasians were confirmed. These results suggest that miR-221 may be a useful indicator for diagnosing patients with MM. In conclusion, miR-221 is useful in the diagnosis and determining the prognosis of multiple myeloma in Koreans.
Abstract
Multiple myeloma (MM) is the leading cause of death among hematologic neoplasms. Recently, microRNA has been reported to be useful in the diagnosis of multiple myeloma. This study examined whether miR-221 could be used as a diagnostic marker for multiple myeloma. The study was performed on 20 patients with multiple myeloma without any other hematological diseases. MicroRNA extraction was performed using formalin-fixed paraffin-embedded (FFPE) tissues obtained from the bone marrow of patients with multiple myeloma. miR-15a, miR-16, miR-21, miR-181a, and miR-221 were selected as the microRNA target genes for multiple myeloma. The significance of microRNA was based on a fold change of ＜1.5. To quantify the fold changes, data normalized to the human gene, SNORD43, were used as the values of the patient group. Fold change values greater than 1.5 were defined as “overexpression”, whereas values less than -1.5 were defined as “underexpression”. Of note, 65.0% (13/20) of samples showed significant “overexpression” in the levels of miR-221 expression and plasma cells with a group of more and less than 30% in MM patients did not show any significance of plasma cell (P＜0.05). The results of other studies showing a correlation between the expression of miR-221 and MM in Caucasians were confirmed. These results suggest that miR-221 may be a useful indicator for diagnosing patients with MM. In conclusion, miR-221 is useful in the diagnosis and determining the prognosis of multiple myeloma in Koreans.
참고문헌 (32)
- Alexander DD, "Multiple myeloma: a review of the epidemiologic literature", Int J Cancer, 120(Suppl 12), pp.40~61 (2007)[DOI]
- Ribatti D, "Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma", Oncogene, 25, pp.4257~4266 (2006)[DOI]
- Greipp PR, "International staging system for multiple myeloma", J Clin Oncol, 23, pp.3412~3420 (2005)[DOI]
- Chng WJ1, "Targeted therapy in multiple myeloma", Cancer Control, 12, pp.91~104 (2005)
- Raab MS, "Multiple myeloma", Lancet, 374, pp.324~339 (2009)[DOI]
- Kumar S, "Multiple myeloma-current issues and controversies", Cancer Treat Rev, 36(Suppl 2), pp.3~11 (2010)[DOI]
- Kyle RA, "A long-term study of prognosis in monoclonal gammopathy of undetermined significance", N Engl J Med, 346, pp.564~569 (2002)[DOI]
- Kyle RA, "Prevalence of monoclonalgammopathy of undetermined significance", N Engl J Med, 354, pp.1362~1369 (2006)[DOI]
- Baffa R, "MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets", J Pathol, 219, pp.214~221 (2009)[DOI]
- Kota J, "Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model", Cell, 137, pp.1005~1017 (2009)[DOI]
- Schetter AJ, "MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma", JAMA, 299, pp.425~436 (2008)
- Garzon R, "MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia", Blood, 111, pp.3183~3189 (2008)[DOI]
- Porkka KP, "MicroRNA expression profiling in prostate cancer", Cancer Res, 67, pp.6130~6135 (2007)[DOI]
- Iorio MV, "MicroRNA signatures in human ovarian cancer", Cancer Res, 67, pp.8699~8707 (2007)[DOI]
- Mattie MD, "Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies", Mol Cancer, 5, pp.24~ (2006)[DOI]
- Roccaro AM, "MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma", Blood, 113, pp.6669~6680 (2009)[DOI]
- Croce CM, "Causes and consequences of microRNA dysregulation in cancer", Nat Rev Genet, 10, pp.704~714 (2009)[DOI]
- Vasilatou D, "The role of microRNAs in normal and malignant hematopoiesis", Eur J Haematol, 84, pp.1~16 (2009)
- Corthals SL, "Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma", Leuk Res, 34, pp.677~681 (2010)[DOI]
- Kim YK, "Functional links between clustered microRNAs: suppression of cell cycle inhibitors by microRNA clusters in gastric cancer", Nucleic Acids Res, 37, pp.1672~1681 (2009)[DOI]
- Chang HJ, "The relationship between the progression of colorectal cancer and microRNA polymorphisms", Korean J Clin Oncol, 7, pp.50~57 (2011)[DOI]
- 손지웅, "MicroRNA Expression Profiles in Korean Non-Small Cell Lung Cancer", Tuberculosis and Respiratory Diseases, 67(5), pp.413~421 (2009), 대한결핵및호흡기학회
- Lee HJ, "MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features", World J Surg Oncol, 10, pp.174~ (2012)[DOI]
- Loffler D, "Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediatde induction of microRNA-21 through a highly conserved enhancer", Blood, 110, pp.1330~1333 (2007)[DOI]
- 최우순, "다발성골수종 환자의 파라핀포매조직에서 MicroRNA 발현", 대한임상검사과학회지, 47(4), pp.292~297 (2015), 대한임상검사과학회
- Farazi TA, "miRNAs in human cancer", J Pathol, 223, pp.102~115 (2011)[DOI]
- Tan KS, "Expression profile of microRNAs in young stroke patients", PLoS One, 4, pp.e7689~ (2009)[DOI]
- Rajkumar SV, "International myeloma working group updated criteria for the diagnosis of multiple myeloma", Lancet Oncol, 15, pp.538~548 (2014)[DOI]
- Wu W, "MicroRNA: potential targets for the tevelopment of novel drugs?", Drugs R D, 10, pp.1~8 (2010)[DOI]
- Di Martino MT, "In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells", PLoS One, 9, pp.e89659~ (2014)[DOI]
- Went P, "Plasma cell quantification in bone marrow by computer-assisted image analysis", Histol Histopathol, 21, pp.951~956 (2006)
- Xiang T, "Identification of four potential predicting miRNA biomarkers for multiple myeloma from published datasets", Peer J, 31, pp.e2831~ (2017)